Allakos Stock News

The company announced disappointing results from two clinical studies.

Allakos Inc (NASDAQ: ALLK) announced its results from Enigma II, Phase III placebo-controlled, double-blind clinical research of lirentelimab on people battling EG (eosinophilic gastritis) and went

Learn what's setting the tone on Wall Street Wednesday.

Allakos Inc (NASDAQ: ALLK) is trading significantly lower Wednesday after the company announced ENIGMA 2 and KRYPTOS studies did not achieve statistical significance on the patient reported symptomat

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With Inflammation In Digestive Tract Alla

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos''s Lirentelimab Flunks Late-Stage Studies In Patients With Inflammation In Digestive Tract Allakos, Inc. (NASDAQ: ALLK ) announced data from ENIGMA 2 Phase 3 study of lirentelimab in patients with biopsy confirmed eosinophilic gastritis and/or eosinophilic duodenitis and KRYPTOS Phase 2/3 study of lirentelimab in patients with biopsy-confirmed eosinophilic esophagitis. Both ENIGMA 2 and KRYPTOS studies met their histologic co-primary endpoints, but did not achieve statistical significance on the patient reported symptomatic co-primary endpoints. The stock was down 7.69% to $77.90 in premarket trading. FDA Imposes Clinical Hold On Injectable Form Of Gilead''s HIV Drug Candidate Due to Concerns Over Vial Quality Gilead Sciences, Inc. (NASDAQ: GILD ) announced that the U.S. Food and Drug Administration has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV pre-exposure prophylaxis.

Allakos' recent study results have sent ALLK stock straight to the bottom. Here's what investors should know right now.

Allakos Inc (NASDAQ: ALLK) reported data from ENIGMA 2 Phase 3 study of lirentelimab in eosinophilic gastritis (EG) or eosinophilic duodenitis (EoD) and KRYPTOS Phase 2/3 study of lirentelimab in eos

The stock price of Allakos Inc (NASDAQ: ALLK) fell by over 85% pre-market today. This is why it happened.

Lirentelimab met histologic co-primary endpoints but missed symptomatic co-primary endpoints in both ENIGMA and KRYPTOS studies Lirentelimab met histologic co-primary endpoints but missed symptomatic

Lirentelimab met histologic co-primary endpoints but missed symptomatic co-primary endpoints in both ENIGMA and KRYPTOS studies Lirentelimab met histologic co-primary endpoints but missed symptomatic co-primary endpoints in both ENIGMA and KRYPTOS studies

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

Allakos Inc. (NASDAQ:ALLK) was the target of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,690,000 shares, a decrease of 26.5% from the November 15th total of 2,300,000 shares. Based on an average daily volume of 268,000 shares, the days-to-cover ratio is currently []

Allakos Inc. (NASDAQ:ALLK) traded up 6.3% on Monday after Bank of America raised their price target on the stock from $145.00 to $155.00. Bank of America currently has a buy rating on the stock. Allakos traded as high as $77.53 and last traded at $77.39. 2,470 shares were traded during mid-day trading, a decline of […]